Robert Z. Orlowski, MD, PhD - Driving Change in Multiple Myeloma: Updates on Novel Agent Classes and Next-Generation Therapeutics - a podcast by PVI, PeerView Institute for Medical Education
from 2019-08-14T18:00
Go online to PeerView.com/TXD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in the management of MM discusses the implications of recent efficacy and safety data that support the ongoing integration and use of several innovative treatments, such as antibody-based therapies, next-generation IMiDs and proteasome inhibitors, and novel therapies directed against intracellular targets. The expert also provides a review of the overall shape of MM therapy in newly diagnosed and relapsed disease, and discusses strategies to manage treatment-related adverse effects. Upon completion of this activity, participants will be able to: Summarize updated evidence on the use of novel agent classes and next-generation therapeutics in multiple myeloma (MM), including proteasome inhibitors, immunomodulators (IMiDs), novel antibodies, and targeted agents, Select appropriate therapy in patients with newly diagnosed MM, including those requiring eradication of MRD or treatment for high-risk disease, Recommend therapy with novel components for patients with early relapse or treatment-refractory MM, Manage treatment-related adverse events in patients with MM who are receiving novel therapeutics as part of their care.
Further episodes of PeerView Immunology
Further podcasts by PVI, PeerView Institute for Medical Education